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Many features of chronic kidney disease may be reversed, but
it is unclear whether advanced lesions, such as adhesions of
sclerotic glomerular tufts to Bowman’s capsule (synechiae),
can resolve during treatment. We previously showed, using a
renal ablation model, that the renoprotective effect of the
AT-1 receptor blocker, losartan, is dose-dependent. Here we
determined if moderate and advanced glomerular lesions,
associated with streptozotocin-induced diabetes, regress
with conventional or high-dose losartan treatment. Using
daily insulin injection for 10 months, we maintained diabetic
adult male Munich-Wistar rats in a state of moderate
hyperglycemia. Following this period, some rats continued to
receive insulin with or without conventional or high-dose
losartan for an additional 2 months. Diabetic rats pretreated
with insulin for 10 months and age-matched non-diabetic
rats served as controls. Mesangial expansion was found in
the control diabetic rats and was exacerbated in those rats
maintained on only insulin for an additional 2 months.
Conventional and high-dose losartan treatments reduced this
mesangial expansion and the severity of synechiae lesions
below that found prior to treatment; however, the frequency
of the latter was unchanged. There was no dose–response
effect of losartan. Our results show that regression of
mesangial expansion and contraction of sclerotic lesions is
feasible in the treatment of diabetes, but complete resolution
of advanced glomerulosclerosis may be hard to achieve.
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In recent years, the concept that regression of chronic kidney
disease (CKD) can be achieved has been intensely dis-
cussed.1–6 This exciting possibility was first shown in concrete
terms by Fioretto et al.3, who described regression of
moderate diabetic glomerulopathy 10 years after pancreatic
transplantation. More recently, several studies utilizing
experimental models of diabetic and nondiabetic CKD have
provided additional evidence that continuous suppression of
the renin–angiotensin system (RAS) with angiotensin I-
converting enzyme inhibitors or angiotensin II (Ang II)
receptor blockers can not only detain but even revert
progressive renal injury.1,2 However, interpretation of these
observations is often clouded by the lack of a precise
definition of the attending lesions. The term ‘glomerulo-
sclerosis’ (GS) is utilized in a somewhat loose manner, and
may refer to an ample spectrum of glomerular lesions,
ranging from simple deposition of extracellular matrix at the
mesangial area to severe occlusion of capillary loops with
formation of synechiae with Bowman’s capsule. Irrespective
of nomenclature, it is presently unclear whether more
‘advanced’ lesions can regress, or whether reversal of injury
is instead restricted to those situations involving only
relatively ‘moderate’ lesions such as mesangial expansion.
This aspect acquires special importance whereas recent
evidence indicates that a substantial fraction of diabetic
patients with microalbuminuria but not overt proteinuria
exhibit nevertheless decreased renal function and/or subse-
quent progression to severe CKD, suggesting that ‘advanced’
injury might already be present in a large fraction of
glomeruli even in apparently incipient diabetic nephropa-
thy.7,8 A more precise knowledge of which lesions are indeed
reversible is therefore highly desirable.
It is now well established that therapy with angiotensin I-
converting enzyme inhibitors and/or Ang II receptor blockers
has strategic importance in the clinical management of CKD.
However, it is currently unclear whether higher-than-usual
doses of these compounds are necessary to promote
renoprotection and, especially, regression of chronic renal
injury. A number of experimental1,4,9 and clinical10–12 studies
have reported evidence that these beneficial effects of
angiotensin I-converting enzyme inhibitors and Ang II
receptor blockers are indeed dose responsive. We have shown
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recently13 that an extremely high dose (500 mg/kg) of the Ang
II receptor blocker, losartan potassium (L), can afford more
effective preservation of renal structure than a ‘conventional’
dose (50 mg/kg) in rats with 5/6ths renal ablation (Nx).
However, whether such unusually high doses would provide
similar protection in rats with diabetic nephropathy has not
been investigated.
The present study was performed nearly 1 year after
induction of diabetes mellitus with streptozotocin (STZ) to
allow enough time for ‘advanced’ glomerular injury to
develop and to investigate: (1) whether either ‘advanced’ or
‘moderate’ lesions can regress on treatment with L and (2)
whether stabilization or regression of glomerular injury with
L follows a dose–response relationship.
RESULTS
The most relevant baseline characteristics, observed at 10
months of DM in groups C, DMUNT, DML50, and DML500,
along with those obtained in group DMPRE (pretreatment
reference), are given in Table 1. As expected, body weight was
reduced, whereas blood glucose (BG) concentration was
elevated in the diabetic groups, compared with nondiabetic
controls. Tail-cuff pressure (TCP) was similar among groups
at this time. As described under section Materials and
Methods, the diabetic groups were assembled in such a way
that no significant difference among them was observed at
this time regarding urinary albumin excretion rate (UalbV),
which was markedly elevated relative to C. Likewise, no
significant difference among DM groups was noted regarding
TCP or BG.
Figure 1 depicts the time course of BG, TCP, and UalbV
along the entire study. There was no difference among
diabetic groups regarding these parameters before the
initiation of treatments at 10 months of DM. At the end of
the treatment period, BG remained similarly elevated in the
diabetic groups compared with C (Figure 1a). There was a
moderate fall in TCP in both losartan-treated groups
(120±4 mm Hg in group DML50 and 115±4 in group
DML500, Po0.05 versus C). No significant difference in TCP
was observed between groups DML50 and DML500 at the end
of treatment (Figure 1b). UalbV rose steadily compared with
C in all diabetic groups until 10 months of DM, when
treatments were started (Figure 1c). During the treatment
period, UalbV remained markedly elevated in untreated rats
(group DMUNT), whereas albuminuria regressed to values
undistinguishable from control with both Losartan doses
(Figure 1c).
Histomorphometric and immunohistochemical studies
The fractional mesangial area was significantly increased in
the DMPRE group compared with controls (16.9±1.0 versus
10.3±0.9 in C, Po0.05) (Figure 2a and c), and increased
further in the DMUNT group, now reaching values more than
twice as high as in C, and significantly higher than in the
Table 1 | Baseline characteristics of groups DMPRE, DMUNT,
DML50, and DML500 immediately before the start of
treatments (at 10 months of DM)
BW (g) TCP (mm Hg) BG (mg/100 ml) UalbV (mg/day)
C (n=12) 417±10 135±2 92±4 24±3
DMPRE (n=10) 342±8
a 134±2 405±16a 112±16a
DMUNT (n=8) 347±8
a 130±2 360±18a 114±22a
DML50 (n=11) 346±5
a 135±1 370±15a 111±17a
DML500 (n=12) 357±3
a 135±2 420±17a 113±19a
BG, blood glucose concentration; BW, body weight; TCP, tail-cuff pressure; UalbV,
urine albumin excretion rate.
aPo0.05 versus C.
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Figure 1 | Blood glucose, tail-cuff and albuminuria. (a) Time course of blood glucose concentration, (b) tail-cuff pressure, and (c)
albuminuria in groups C (filled circles), DMPRE (open circles), DMUNT (open squares), DML50 (filled squares), and DML500 (filled triangles).
Treatment was given only during the period represented by the shaded area (from 10 to 12 months of DM). Group DMPRE was followed until
10 months of DM only. No significant difference among groups was observed regarding BG, TCP, or UalbV before the treatment period.
aPo0.05 versus C, bPo0.05 versus 10-month (pretreatment) value, and cPo0.05 versus DMUNT.
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pretreatment group (21.8±1.4, Po0.05 versus C and
DMPRE). The fractional mesangial area was significantly
lower in groups DML50 and DML500 than in group DMPRE
(12.5±0.7 and 12.7±1.2, respectively, Po0.05 versus
DMPRE), indicating that Losartan treatment promoted
regression of mesangial expansion. No significant difference
between the beneficial effects of the two Losartan doses
employed was observed. The extent of segmental GS,
estimated by the glomerulosclerosis index (GSI), was
markedly increased (Figure 2b and d) in the DMPRE group
(24.4±3.0 versus 7.9±0.6 in C, Po0.05). The GSI was
further augmented in group DMunt (50.5±7.1, Po0.05
versus C and DMPre). As with the fractional mesangial area,
GSI dropped below pretreatment values with both losartan
doses (11.3±1.4 in DML50 and 14.1±2.4 in DML500, Po0.05
versus DMPRE). Again, no difference was noted between
groups DML50 and DML500. When segmental GS (Figure 2b
and e) was evaluated by the frequency of sclerotic lesions
(percentage of glomerulosclerosis, %GS), a sharp increase
above control was observed in group DMPRE (7.1±1.4 versus
1.7±0.4 in C, Po0.05), with a marked additional elevation
in group DMUNT (20.9±3.8, Po0.05 versus C and DMPRE).
In groups DML50 and DML500, the %GS was significantly
lower than in group DMUNT (6.0±2.0 and 7.1±1.6,
respectively, Po0.05 versus C and DMUNT), again indicating
a salutary effect of Losartan treatment. Unlike mesangial
expansion and the GSI, however, the %GS did not fall below
pretreatment levels in losartan-treated rats, indicating that,
although the extent of glomerular sclerotic lesions regressed
with treatment, the frequency of these lesions did not. As in
previous studies, the fractional cortical interstitial area
(%INT) in the DM groups was not significantly different
from control, with only a numerical trend toward interstitial
expansion in the DMUNT group (2.1±1% versus 0.6±0.1 in
C and 0.6±0.1 in DMPRE, P40.05). Losartan treatment
exerted no significant effect on %INT (1.2±0.4 in DML50
and 1.5±0.3 in DML500, P40.05 versus DMUNT).
Data obtained by immunohistochemical detection of
macrophages are shown in Figure 3. The number of
macrophages detected in glomeruli and at the cortical
interstitium was similar to control in group DMPRE, but
was significantly increased at both locations in untreated DM
rats observed 12 months after STZ injection (group DMUNT).
Glomerular macrophage infiltration was prevented by treatment
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Figure 2 | Histological studies. (a, b) Representative glomeruli, stained by the PAS reaction, illustrating mesangial expansion (a) and
segmental sclerotic lesions (b) at the end of the study (12 months of DM). (c) Bar graph representation of the mesangial fractional areas at
12 months of DM, (d) bar graph representation of the glomerulosclerosis index (measuring frequency and extent of segmental sclerotic
lesions) at 12 months of DM, and (e) bar graph representation of the frequency of glomeruli with sclerotic injury (% glomeruli with
segmental sclerotic lesions) at 12 months of DM. aPo0.05 versus C, bPo0.05 versus respective 10-month (pretreatment) value, and cPo0.05
versus DMUNT.
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with either dose of Losartan. Likewise, both drug regimens
prevented macrophage infiltration at the renal interstitial area,
although only in the group treated with the high dose of
Losartan was the number of interstitial macrophages signifi-
cantly lower than in untreated DMUNT rats.
No significant difference was found among groups at the
end of the study regarding plasma creatinine or potassium
concentration. Plasma aldosterone concentration was not
significantly different from control in group DMPRE
(659±120 pg/ml versus 489±75 in C, P40.05), but was
significantly elevated in group DMUNT (971±141 pg/ml,
Po0.05 versus C). Losartan treatment reduced plasma
aldosterone concentration to levels not significantly
different from those observed in C or DMPRE (508±81 pg/
ml in DML50 and 524±85 in DML500, Po0.05 versus
DMUNT).
DISCUSSION
In consistency with previous observations,14–16 diabetic rats
exhibited progressive albuminuria that reached, after 10
months of DM, values more than fivefold higher than in age-
matched controls, and 100 times higher than in young
controls. The presence of glomerular injury was evident in
DM rats 10 months after STZ injection. The most frequent
modality of lesion in these rats was diffuse mesangial
expansion, as indicated by a marked increase in the mean
fractional mesangial area compared with nondiabetic con-
trols. Sclerotic lesions associated with synechiae with Bow-
man’s capsule were observed in about 5% of the glomeruli at
this time point. Accordingly, the GSI was threefold higher in
these rats than in nondiabetic controls. However, it must be
noted that, in consistency with previous findings15–17 diabetic
rats exhibited little or no interstitial expansion or inflamma-
tion, indicating that renal injury was essentially confined to
the glomeruli at this phase.
The progressive nature of the nephropathy is stressed by
the substantial worsening of glomerular injury observed in
untreated DM rats at 12 months, compared with that seen at
10 months, after diabetes induction. Glomerular macrophage
infiltration, mesangial expansion and GS were clearly
exacerbated at this time, although elevation of serum
creatinine was not observed. Likewise, macrophage infiltra-
tion of the interstitial area was now evident, in all likelihood
heralding the imminent development of interstitial expan-
sion/inflammation. Accordingly, the percent interstitial area
was numerically, although not significantly, increased in this
group. Of note, the circulating levels of aldosterone were
elevated in untreated DM rats, although no sign of
extracellular volume depletion was ever seen in these animals.
Given the available evidence that aldosterone exerts a
profibrotic action in CKD18,19, the finding of hyperaldoster-
onism in group DMUNT is consistent with the view that
incipient renal fibrosis may already be developing in these
animals at 10 months of DM.
C
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Figure 3 | Macrophage infiltration of renal tissue. (a and b) Representative glomeruli illustrating the expression of the macrophage-
specific ED-1 antigen at glomerular (a) and interstitial (b) areas. (c and d) Bar graphs showing the quantitative analysis of the expression of
glomerular and interstitial ED-1, respectively. aPo0.05 versus C, bPo0.05 versus DMPRE (pretreatment), and cPo0.05 versus DMUNT.
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Irrespective of dose, Losartan treatment started 10 months
after STZ injection sharply reduced albuminuria, which
regressed to levels not significantly different compared with
nondiabetic controls, indicating restoration of the glomerular
barrier properties. The exact mechanisms of this beneficial
effect are unclear. It is well established that suppressors of the
RAS markedly lower glomerular pressure,14,15,20 thus lessen-
ing the mechanical stress directly imposed on podocytes.
Moreover, losartan may have more direct effects on
podocytes, which are known to express the AT1 receptor,
particularly when exposed to high glucose concentrations,21
and to generate Ang II under stretching.22 Losartan treatment
may have provided additional renoprotection by abrogating
the multiple proinflammatory consequences of AT1 activa-
tion.23,24
Losartan therapy promoted a clear regression of mesangial
expansion compared with pretreatment values. These find-
ings are in agreement with previous observations made in
diabetic patients, as well as in diabetic and nondiabetic
experimental nephropathy,1,3–6,25,26 and indicate that the
mesangial enlargement observed in association with the STZ-
induced diabetes model is a readily reversible process. The
mechanisms underlying the regression of mesangial expan-
sion by losartan treatment are yet to be determined. Losartan
treatment can arrest the abnormal synthesis of mesangial
matrix by attenuating or abolishing glomerular hypertension
and its local inflammatory consequences, such as activation
of the RAS,27 enhanced proliferation of mesangial cells28,29,
and increased production of transforming growth factor-b30
and mesangial matrix.31 In addition, suppression of the RAS
has been shown to restore the glomerular expression of
matrix metalloproteinases such as MMP-2 and MMP-9
(MMPs), which is depressed in diabetic kidney,32 and to
decrease that of plasminogen activator inhibitor 1 in
nondiabetic kidney disease,33 thus allowing quick degrada-
tion of the excess mesangial matrix.
Since the early observations on the regression of GS, it has
been questioned whether this process can occur even after the
tuft architecture has undergone severe distortion.8,25,26 The
discussion of this important aspect is often complicated by
the lack of a clear-cut distinction between ‘moderate’ and
‘severe’ GS. To obviate this problem, the term ‘GS’ was
reserved in the present study to lesions involving not only
matrix deposition at the mesangial area but also confluence
of deposits, occlusion of capillary loops and, especially, the
presence of synechiae of the tuft with Bowman’s capsule, used
as an exclusion criterion. When the effect of losartan
treatment on GS was analyzed using the GSI, the results
largely agreed with those obtained for mesangial expansion:
the GSI was reduced to levels significantly lower than before
treatment, again indicating regression of glomerular injury.
However, when results were expressed in terms of the percent
of glomeruli showing sclerosing lesions, a different picture
emerged: although the %GS was significantly lower in
losartan-treated than in untreated diabetic rats, indicating
efficient renoprotection, it was similar to that observed
before treatment, a finding seemingly inconsistent with
regression of GS. This is only an apparent contradiction.
‘True’ GS was invariably associated with exuberant expansion
of the mesangial matrix in the vicinity of the synechiae. Since
the GSI measures both the frequency and the extent of the
sclerotic lesions, its decline on losartan treatment inevitably
reflects in part the simultaneous clearance of the excess
mesangial matrix. By contrast, the formation of synechiae
involves a profound local rearrangement of the glomerular
structure, with podocyte effacement and invasion by parietal
cells, along with periglomerular inflammation and fibrosis.8
Conceivably, such alterations, as well as more advanced
structural injury such as interstitial fibrosis, are less prone to
regression than simple mesangial expansion, since the action
of degrading enzymes, though efficient to clear even large
deposits of matrix components, may be insufficient to restore
the original structure of the glomerular tuft once it has been
severely compromised. Thus, the glomerular sclerotic lesions
associated with synechiae, observed at 10 months of diabetes
(measured by the %GS), appear to have persisted despite the
contraction of the adjacent mesangial area, which probably
contributed to diminish the GSI. However, we cannot
exclude the possibility that regression of glomerular syne-
chiae would also be achieved had a longer treatment with
losartan been carried out.
Despite the well-known limitations of STZ diabetes as a
model of human disease, such as lack of nodular lesions and
interstitial inflammation, the regression of mesangial expan-
sion observed in the present study is in agreement with
previous clinical and experimental observations1–6 and have
well-defined implications. Microalbuminuric diabetic pa-
tients with well-preserved renal function may exhibit marked
mesangial expansion, which can regress on adequate
pharmacological intervention and/or rigorous control of
the metabolic disturbance.3,34 However, even in those
patients with only incipient diabetic nephropathy, a sub-
stantial fraction of the glomeruli may already exhibit
structural injury, less promptly reversible than mesangial
expansion even if adequate therapeutic measures are taken. It
must be noted that podocyte dysfunction and even reduction
of the podocyte number can occur in diabetic patients at a
time when GFR is still normal or even increased.35,36 As
podocyte loss can lead to denudation of the glomerular
basement membrane and consequent adherence of the tuft to
Bowman’s capsule,8 it is likely that even patients with
microalbuminuria already have glomerular synechiae in a
significant proportion of glomeruli. This may be one of the
reasons why unrelenting decline of renal function was
observed in a substantial fraction of diabetic patients who
initially presented with microalbuminuria only.7 Conversely,
podocyte protection may explain the reason why therapy
with an AT1 receptor blocker prevents the transition from
microalbuminuria to overt renal disease in type 2 diabetic
patients.37
Both doses of losartan employed in this study promoted
marked reduction of albuminuria in diabetic rats, although
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the high dose was slightly more efficient. Likewise, the degree
of preservation of the renal structure obtained in the present
study with the two regimens was essentially the same. This
observation is in contrast with the clear-cut dose–response
effect observed with losartan therapy in the Nx model.13 The
reasons for this discrepancy are unclear. However, it must be
noted that, in the Nx model, marked expansion and
inflammation of the interstitial area can be observed, since
very early stages, in addition to glomerular and vascular
injury.13,38 Intense expression of the AT1 receptor is observed
at these inflamed interstitial areas,39 which may constitute an
exquisitely sensitive target for the high-dose losartan therapy.
As such target was absent in the present study, a possible
beneficial effect of the high-dose losartan regimen may have
gone undetected.
In summary, the renal structural injury observed after 10
months of STZ-induced diabetes was essentially confined to
the glomeruli. The most frequent modality of glomerular
injury, mesangial expansion, regressed promptly on losartan
treatment. The frequency of sclerotic lesions associated with
synechiae to Bowman’s capsule was unchanged by this
therapy, although their severity did diminish. The renopro-
tection associated with losartan treatment was not dependent
on dose, although a dose–response effect might be expected
in rats with more advanced disease, especially if accompanied
by interstitial injury. Treatment with suppressors of the RAS
can promote regression of mesangial expansion and contrac-
tion of glomerular sclerotic lesions in diabetic nephropathy.
MATERIALS AND METHODS
Adult male Munich–Wistar rats of approximately 2 months of age
obtained from a local colony, and weighing initially 220–280 g, were
used in this study. Rats were maintained at 23±4 1C, with relative
air humidity at 60±5%, and under a 12/12 h day–night cycle. All
animals received standard rat chow (0.5% Na, 22% protein) and free
access to tap water. A total of 41 rats were made diabetic by a single
dose of STZ, 65 mg/kg (Sigma Chemical, St Louis, MO, USA),
through a tail vein, under light anesthesia. The presence of diabetes
was confirmed 2 days later by reflectometric measurement of tail
BG. Diabetic rats received daily injections of NPH insulin in mid
afternoon, in doses adjusted individually (ranging from 1 to 4 units)
so as to keep BG between 300 and 450 mg/100 ml. BG was
determined by reflectometry weekly. L was dissolved in the
drinking water at 50 mg/kg/day (‘standard’ dose) or 500 mg/kg/day
(‘high’ dose). In preliminary experiments, the latter was found to be
the maximum dose that the rats would tolerate without growth
stunting or deterioration of their general condition. All experi-
mental procedures were approved by the local Research Ethics
Committee (CAPPesq process no. 918/05) and conducted in
strict conformity with local institutional guidelines and with
international standards for the manipulation and care of laboratory
animals.
Experimental groups
Ten months after STZ injection (to allow the development of
substantial glomerular injury), DM rats were divided in four groups
in such a way that the variation of the mean urinary albumin
excretion rate (UalbV) among experimental groups did not exceed
5%. The groups were: DMPRE, diabetic rats utilized as a
pretreatment reference and followed no further; DMUNT (un-
treated), diabetic rats receiving no treatment other than insulin;
DML50, DM rats receiving insulin and L in the drinking water,
50 mg/kg/day; DML500, diabetic rats receiving insulin and L in the
drinking water, 500 mg/kg/day. Age-matched nondiabetic rats given
no pharmacological treatment were used as controls (group C).
Water consumption was monitored daily, and the concentration of L
in the drinking water was adjusted so as to keep dosages constant.
All groups except group DMpre were followed during 2 months
(until 12 months after STZ).
Experimental protocol
A total of 8 DMUNT, 11 DML50, 12 DML500, and 12 C rats were
followed from 10 until 12 months after DM induction, with
monthly assessment of UalbV and TCP. At the end of the study, rats
were anesthetized with pentobarbital, 50 mg/kg i.p., and blood
samples were drawn from the abdominal aorta for determination of
serum creatinine, plasma potassium, and aldosterone. The left
kidney was then retrogradely perfused in situ with Duboscq-Brazil
solution at the measured arterial pressure, after a brief washout with
saline to remove blood from renal vessels. After perfusion–fixation,
the kidney was weighted and two midcoronal slices were postfixed in
buffered 10% formaldehyde solution. The renal tissue was then
embedded in paraffin by standard sequential techniques for
assessment of glomerular and interstitial injury, as well as for
immunohistochemical analysis. Identical procedures were followed
for group DMPRE (pretreatment reference), studied 10 months after
STZ injection.
Histomorphometric and immunohistochemical analysis
For assessment of glomerular injury, 2- to 3-mm-thick sections,
stained by the periodic acid-Schiff technique, were utilized. Two
distinct modalities of glomerular injury were identified in this study:
(1) mesangial expansion was defined as a diffuse accumulation of
periodic acid-Schiff positive material in the mesangial area; and (2)
GS was defined as the presence of dense, abundant deposition of
periodic acid-Schiff positive material at the glomerular tuft, with
occlusion of capillary loops, segmental hyalinization and the
obligatory presence of at least one synechia of the glomerular tuft
with Bowman’s capsule. The use of the latter criterion was intended
to avoid confusion between simple mesangial expansion and GS.
The fractional mesangial area was evaluated in each rat by
examining 50 consecutive glomeruli using a point-counting
technique.40 GS was evaluated by two different methods: (1)
determination of the percentage of glomeruli exhibiting sclerotic
lesions (%GS); (2) calculation of a GS index (GSI) for each rat by
attributing to each glomerulus a score and computing a weighted
average of these scores, as described previously.39 For the calculation
of either %GS or the GSI, 200 consecutive glomeruli were examined
for each rat. Glomerular lesions without synechiae were not
computed as sclerotic, regardless of their area. All histomorpho-
metric evaluations were performed blindly by a single observer. The
%INT was evaluated in Masson-stained sections by a point-counting
technique,40 examining 25 consecutive microscopic fields, at a final
magnification of  100, under a 144 point grid.
Immunohistochemical detection of macrophages was performed
on 4-mm-thick paraffin-embedded renal sections mounted on glass
slides coated with 2% gelatin. Sections were initially deparaffinized
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and rehydrated using standard techniques, then exposed to
microwave irradiation in citrate buffer to enhance antigen retrieval,
and preincubated with 5% normal rabbit serum in Tris-buffered
saline, to prevent nonspecific binding. Incubation with the primary
antibody was always carried out overnight at 4 1C in a humidified
chamber. Negative control experiments were performed by omitting
incubation with the primary antibody. Macrophages were detected
with a monoclonal mouse anti-rat ED-1 antibody (Serotec, Oxford,
UK). After washing, sections were incubated with rabbit anti-mouse
immunoglobulin (Dako, Glostrup, Denmark), then with an alkaline
phosphatase anti-alkaline phosphatase (Dako) complex. Finally,
sections were developed with a fast-red dye solution, counterstained
with Mayer’s hemalaum, and covered with Kaiser’s glycerin–gelatin
(Merck, Darmstadt, Germany). The extent of ED-1 positive cell
infiltration was evaluated at  250 magnification and expressed as
cells/mm2. For each section, 25 microscopic fields, each correspond-
ing to an area of 0.13 mm2, were examined.
Statistical analysis
One-way analysis of variance (ANOVA) with pairwise posttest
comparison according to the Newman–Keuls method was used in
this study. Since UalbV and GSI exhibited non-Gaussian distribu-
tions, log transformation of these parameters was performed before
statistical analysis. The Pearson coefficient was calculated for linear
correlation analysis. P levels of 0.05 or less were considered
significant.
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